Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Next Previous
Search
Drug Profile

Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF-5993; ICS/LABA/LAMA; Riarify; Trimbow

Latest Information Update: 08 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Registered Asthma

Most Recent Events

  • 08 Jan 2025 Beclometasone/formoterol/glycopyrrolate is still in phase-III clinical trials in Chronic obstructive pulmonary disease in Czech Republic (Inhalation) (EudraCT2020-002389-16) (NCT04320342)
  • 09 Sep 2023 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Asthma(In volunteers) in USA (Inhalation, Powder)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top